EP0904082A4 - Kombinationstherapie zur verminderung der mit herz-kreislauferkrankungen einhergenden risiken - Google Patents

Kombinationstherapie zur verminderung der mit herz-kreislauferkrankungen einhergenden risiken

Info

Publication number
EP0904082A4
EP0904082A4 EP97918595A EP97918595A EP0904082A4 EP 0904082 A4 EP0904082 A4 EP 0904082A4 EP 97918595 A EP97918595 A EP 97918595A EP 97918595 A EP97918595 A EP 97918595A EP 0904082 A4 EP0904082 A4 EP 0904082A4
Authority
EP
European Patent Office
Prior art keywords
reducing
combination therapy
cardiovascular disease
risks associated
risks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP97918595A
Other languages
English (en)
French (fr)
Other versions
EP0904082A1 (de
Inventor
Jonathan A Tobert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9612082.9A external-priority patent/GB9612082D0/en
Priority claimed from GBGB9616804.2A external-priority patent/GB9616804D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of EP0904082A1 publication Critical patent/EP0904082A1/de
Publication of EP0904082A4 publication Critical patent/EP0904082A4/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
EP97918595A 1996-04-17 1997-04-14 Kombinationstherapie zur verminderung der mit herz-kreislauferkrankungen einhergenden risiken Ceased EP0904082A4 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US1568996P 1996-04-17 1996-04-17
US15689P 1996-04-17
GBGB9612082.9A GB9612082D0 (en) 1996-06-10 1996-06-10 Combination therapy for reducing the risks associated with cardiovascular disease
GB9612082 1996-06-10
US2097796P 1996-06-24 1996-06-24
US20977P 1996-06-24
GBGB9616804.2A GB9616804D0 (en) 1996-08-09 1996-08-09 Combination therapy for reducing the risks associated with cardiovascular disease
GB9616804 1996-08-09
PCT/US1997/006127 WO1997038694A1 (en) 1996-04-17 1997-04-14 Combination therapy for reducing the risks associated with cardiovascular disease

Publications (2)

Publication Number Publication Date
EP0904082A1 EP0904082A1 (de) 1999-03-31
EP0904082A4 true EP0904082A4 (de) 2001-09-26

Family

ID=27451457

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97918595A Ceased EP0904082A4 (de) 1996-04-17 1997-04-14 Kombinationstherapie zur verminderung der mit herz-kreislauferkrankungen einhergenden risiken

Country Status (5)

Country Link
EP (1) EP0904082A4 (de)
JP (1) JP2000508659A (de)
AU (1) AU732465B2 (de)
CA (1) CA2251972A1 (de)
WO (1) WO1997038694A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0946178A4 (de) * 1996-09-18 2003-05-07 Merck & Co Inc Kombinationstherapie zur verminderung der mit herz-kreislauferkrankungen einhergergenden risiken
US6274603B1 (en) 1997-09-24 2001-08-14 Mcgill University Methods for increasing ApoE levels for the treatment of neurodegenerative disease
BR9813539A (pt) * 1997-12-12 2000-10-10 Warner Lambert Co Combinações de inibidor de lp(a) e estatina anti-hiperlipidêmicas
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
GB2336534A (en) * 1998-04-24 1999-10-27 Alec James Coppen Anti-depressant - Folic Acid Combination
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
ATE326240T2 (de) * 2000-04-10 2006-06-15 Nicholas John Wald Zusammensetzung zur prävention kardiovaskulärer erkrankungen
GB2361185A (en) 2000-04-10 2001-10-17 Nicholas J Wald Pharmaceutical formulation for the prevention of cardiovascular disease
SE0002354D0 (sv) * 2000-06-22 2000-06-22 Astrazeneca Ab New formulation
US6916849B2 (en) 2000-10-23 2005-07-12 Sankyo Company, Limited Compositions for improving lipid content in the blood
AU2001295991A1 (en) * 2000-10-23 2002-05-06 Sankyo Company Limited Compositions for improving lipids in blood
AU2002211005A1 (en) 2000-11-07 2002-05-21 Sankyo Company Limited Lipid peroxide-lowering compositions
CA2427618A1 (en) * 2000-11-29 2002-06-06 Smithkline Beecham Corporation Composition containing statins and calcium for improved cardiovascular health
WO2002047683A1 (fr) * 2000-12-14 2002-06-20 Sankyo Company, Limited Composition ameliorant les lipides dans le sang
CN100369605C (zh) * 2000-12-14 2008-02-20 三共株式会社 血液脂质改善剂组合物
US7037934B2 (en) 2000-12-14 2006-05-02 Sankyo Company, Limited Blood lipid ameliorant composition
TWI284529B (en) * 2000-12-18 2007-08-01 Sankyo Co A composition for lowering triglyceride
SI1353696T1 (sl) * 2001-01-26 2007-04-30 Schering Corp Kombinacije aktivatorja(-ev) peroksisomskega proliferatorja aktivirajocega receptorja (PPAR) in inhibitorja(-ev) absorpcije sterola in oblike zdravljenja za vaskularne indikacije
JP4611622B2 (ja) * 2002-07-11 2011-01-12 第一三共株式会社 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
WO2004006919A1 (ja) * 2002-07-11 2004-01-22 Sankyo Company, Limited 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
AR040588A1 (es) * 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
WO2004012740A1 (ja) * 2002-08-02 2004-02-12 Sankyo Company, Limited HMG-CoAリダクターゼ阻害剤を含有する医薬組成物
JP4607436B2 (ja) * 2002-08-02 2011-01-05 第一三共株式会社 ＨＭＧ−ＣｏＡリダクターゼ阻害剤を含有する医薬組成物
WO2005060975A1 (en) * 2003-12-23 2005-07-07 Medicure International Inc. Combination therapies employing a composition comprising a hmg coa reductase inhibitor and a vitamin b6 related compound
HUE044810T2 (hu) * 2004-03-29 2019-11-28 Wyeth Llc Multi-vitamin és ásványi étrend kiegészítõk
JP2008526783A (ja) * 2005-01-05 2008-07-24 メディキュア・インターナショナル・インコーポレーテッド トリグリセリドレベルを調節するための化合物及び方法
US20080103105A1 (en) * 2006-09-22 2008-05-01 Braincells, Inc. HMG CoA REDUCTASE MEDIATED MODULATION OF NEUROGENESIS
EP2810644A1 (de) 2013-06-06 2014-12-10 Ferrer Internacional, S.A. Orale Formulierung zur Behandlung von Herz-Kreislauf-Erkrankungen
JP6443935B2 (ja) * 2013-07-26 2018-12-26 学校法人 久留米大学 動脈硬化の治療または予防のためのアスピリンおよび葉酸の併用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084482A (en) * 1990-04-10 1992-01-28 The Lithox Corporation Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds
DE4326698A1 (de) * 1993-08-09 1995-03-09 Puetter Medice Chem Pharm Verwendung einer Kombination aus Folsäure, Vitamin B¶6¶ und Vitamin B¶1¶¶2¶ zur Prophylaxe und Therapie von Arteriosklerose

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3895107A (en) * 1970-04-15 1975-07-15 Morrison L M CSA and CSC in man and mammals to inhibit atherosclerosis and the recurrence of cardiovascular incidents in atherosclerotic mammals
US5631401A (en) * 1994-02-09 1997-05-20 Abbott Laboratories Inhibitors of protein farnesyltransferase and squalene synthase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084482A (en) * 1990-04-10 1992-01-28 The Lithox Corporation Methods for inhibiting inflammatory ischemic, thrombotic and cholesterolemic disease response with methionine compounds
DE4326698A1 (de) * 1993-08-09 1995-03-09 Puetter Medice Chem Pharm Verwendung einer Kombination aus Folsäure, Vitamin B¶6¶ und Vitamin B¶1¶¶2¶ zur Prophylaxe und Therapie von Arteriosklerose

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"The Merck Manual of Diagnosis and Therapy", 1992, XP002170578 *
BERG VAN DEN M ET AL: "COMBINED VITAMIN B6 PLUS FOLIC ACID THERAPY IN YOUNG PATIENTS WITH ARTERIOSCLEROSIS AND HYPERHOMOCYSTEINEMIA", JOURNAL OF VASCULAR SURGERY,US,ST. LOUIS, MO, vol. 20, no. 6, December 1994 (1994-12-01), pages 933 - 940, XP000853837, ISSN: 0741-5214 *
BOUSHEY C. ET AL.: "A quantitative assessment of plasma homocysteine as a risk factor for vascular disease", JAMA, vol. 274, no. 13, 4 October 1995 (1995-10-04), pages 1049 - 1057, XP001005592 *
DOBS A. ET AL.: "Lipid-lowering diets in patients, a new HMG-CoA reductase inhibitor: compliance and adequacy", AMERICAN JOURNAL OF CLINICAL NUTRITION, vol. 54, no. 4, October 1991 (1991-10-01), pages 696-700, XP001006920 *
FEHER M D ET AL: "LONG-TERM SAFETY OF STATIN-FIBRATE COMBINATION TREATMENT IN THE MANAGEMENT OF HYPERCHOLESTEROLAEMIA IN PATIENTS WITH CORONARY ARTERY DISEASE", BRITISH HEART JOURNAL,BRITISH MEDICAL ASSOCIATION, LONDON,GB, vol. 74, no. 1, 1995, pages 14 - 17, XP000925445, ISSN: 0007-0769 *
FROHLICH J J: "LIPOPROTEINS AND HOMOCYST(E)INE AS RISK FACTORS FOR ATHEROSCLEROSIS:ASSESSMENT AND TREATMENT", CANADIAN JOURNAL OF CARDIOLOGY,XX,PULSUS GROUP, INC, vol. 11, no. SUPPL. C, 1995, pages 18C - 23C, XP000910760, ISSN: 0828-282X *
MAYER E L ET AL: "HOMOCYSTEINE AND CORONARY ATHEROSCLEROSIS", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY,XX,XX, vol. 27, no. 3, 1 March 1996 (1996-03-01), pages 517 - 527, XP000990693, ISSN: 0735-1097 *
See also references of WO9738694A1 *
TONSTAD S: "Low dose colestipol in adolescents with familial hypercholesterolaemia", ARCHIVES OF DISEASE IN CHILDHOOD, vol. 74, no. 2, February 1996 (1996-02-01), pages 157 - 160, XP001000237 *

Also Published As

Publication number Publication date
AU2666597A (en) 1997-11-07
CA2251972A1 (en) 1997-10-23
WO1997038694A1 (en) 1997-10-23
AU732465B2 (en) 2001-04-26
EP0904082A1 (de) 1999-03-31
JP2000508659A (ja) 2000-07-11

Similar Documents

Publication Publication Date Title
EP0904082A4 (de) Kombinationstherapie zur verminderung der mit herz-kreislauferkrankungen einhergenden risiken
EP0946178A4 (de) Kombinationstherapie zur verminderung der mit herz-kreislauferkrankungen einhergergenden risiken
EG24678A (en) Combination therapy
EP0879279A4 (de) Diabetestherapie
AP2002002661A0 (en) Combination therapy for oesteoporosis
ZA987843B (en) Combination therapy.
IL127306A0 (en) Combination therapy
EP1024696A4 (de) Kombinationstherapie zur reduzierung der mit kardio- und zerebrovaskulären erkrankungen verbundenen risiken
GB9601062D0 (en) The updrifter
GB9421930D0 (en) The barpress
GB9621970D0 (en) Combination therapy for reducing the risks associated with cardiovascular disease
GB9616804D0 (en) Combination therapy for reducing the risks associated with cardiovascular disease
GB9612082D0 (en) Combination therapy for reducing the risks associated with cardiovascular disease
GB9603545D0 (en) The spraymate
ZA977005B (en) Therapeutic uses
GB9617526D0 (en) The hand shield
EG21150A (en) The egtptian lithotriptor k h j
GB9605466D0 (en) Therapy
GB9605525D0 (en) Therapy
GB9602199D0 (en) The seducterlens
GB9613369D0 (en) The Susean
GB9626734D0 (en) The jetlift
GB9602510D0 (en) The easythrow fetchball
GB9601973D0 (en) The clip-it
GB9614951D0 (en) The carrynet

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981117

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/53 A, 7A 61K 31/35 B, 7A 61K 31/505 B, 7A 61P 3/06 B, 7A 61P 9/10 B

A4 Supplementary search report drawn up and despatched

Effective date: 20010814

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20020516

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20051219